更新于：2024-12-09
Nalidixic Acid
萘啶酸
更新于：2024-12-09
概要
基本信息
药物类型 小分子化药 |
别名 1,4-dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid、1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid、1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid + [8] |
作用机制 Bacterial Top II抑制剂(细菌拓扑异构酶II抑制剂) |
在研适应症 |
非在研适应症- |
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1964-03-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C12H12N2O3 |
InChIKeyMHWLWQUZZRMNGJ-UHFFFAOYSA-N |
CAS号389-08-2 |
关联
100 项与 萘啶酸 相关的临床结果
登录后查看更多信息
100 项与 萘啶酸 相关的转化医学
登录后查看更多信息
100 项与 萘啶酸 相关的专利（医药）
登录后查看更多信息
6,186
项与 萘啶酸 相关的文献（医药）2025-01-01·PREVENTIVE VETERINARY MEDICINE
Multiple antibiotic resistance of Salmonella Infantis in the Peruvian poultry production chain: Detection in birds, the farming environment, and chicken carcasses
Article
作者: Lucas, J.R. ; Santa-Cruz, Marlom ; Rodriguez, Jorge ; Davalos, Sebastian ; Lucas, J R ; Condori, Rosario
Poultry can act as a reservoir of Salmonella enterica serotype Infantis (S. Infantis) of clinical and epidemiological importance because it triggers foodborne disease outbreaks and presents antibiotic multiresistance. The present study aimed to determine antimicrobial resistance in S. Infantis isolates from poultry livers, litter and chicken carcasses from Lima, Peru, during 2022-2023. S. Infantis was isolated from 10.1 % (27/267), 4.7 % (4/86), and 8 % (2/25) of the bird, litter and carcass samples, respectively. All isolates showed resistance to nalidixic acid (NA). In addition, 94 %, 76 %, 70 %, 48 %, and 45 % of the isolates showed resistance to tetracycline (TET), amoxicillin (AMX), chloramphenicol (C), gentamicin (GEN) and trimethoprim/sulfamethoxazole (TS), respectively. All isolates showed susceptibility to imipinem and amoxicillin/clavulanic acid. Of the isolates, 93.9 % displayed multidrug resistance. The most frequent resistance pattern was C-AMX-NA-GEN-TET (24.2 %, n=8), determined even from carcass isolates, followed by C-AMX-NA-TET (18.2 %, n=6), and C-AMX-NA-GEN-TS-TET (12.1 %, n=4). The presence of these multidrug-resistant S. Infantis isolates is a threat to food safety and public health.
2024-12-31·Emerging microbes & infections
Genetic characteristics and potential pathogenic agents in
Campylobacter upsaliensis
based on genomic analysis
Article
作者: Ju, Changyan ; Zhou, Guilan ; Li, Ying ; Liu, Chang ; Wang, Hairui ; Chen, Xiaoli ; Zhang, Xin ; Zhang, Jianzhong ; Gu, Yixin ; Shao, Zhujun ; Zhang, Maojun ; Chen, Jing ; Han, Yue
Campylobacter upsaliensis was the most common Campylobacter species in pets' gastrointestinal tracts and has been isolated from patients with bacteremia, hemolytic-uremic syndrome, spontaneous abortion, and Guillain-Barré syndrome. However, the genetic characteristics and the full extent of its significance as a human pathogen remain to be fully understood. This study involved an investigation for genomic analysis of 154 strains from different sources and additional antimicrobial resistance profiles of 26 strains for this species. The genomes contained 1,558-1,971 CDS and the genome sizes were estimated to vary from 1.53 Mb to 1.86 Mb, with an average GC content of 34.71%. The entire analyzed genomes could be divided into three clades (A, B, and C) based on ANI and phylogenomic analysis. Significantly, nearly all strains in Clade B were isolated from patient samples, and the virulence-related sequences FlgD, GmhA, and CdtC might serve as determining factors for the classification of Clade B. Half of the tested isolates had MIC values over 64 μg mL-1 for nalidixic acid, gentamicin, and streptomycin. Isolates from pets in China carried more resistant elements in the genomes. This study both provided a comprehensive profile of C. upsaliensis for its genomic features and suggested some pathogenic agents for human infection with this species.
2024-12-01·Molecular biology reports
High prevalence of plasmid-mediated quinolone resistance in escherichia coli strains producing extended-spectrum beta-lactamases isolated from faeces and urine of pregnant women with acute cystitis
Article
作者: Keshavarz, Kowsar ; Kholdi, Soudeh ; Fathi, Javad ; Darvishvand, Zahra ; Hashemizadeh, Zahra ; Hadadi, Mahtab ; Mohebi, Samane ; Sohrabi, Maryam
BACKGROUND:
Escherichia coli is the most common etiological agent of urinary tract infections (UTIs). Meanwhile, plasmid-mediated quinolone resistance (PMQR) is reported in E. coli isolates producing extended-spectrum β-lactamases (ESBLs). Furthermore, the reservoirs and mechanisms of acquisition of uropathogenic Escherichia coli (UPEC) strains are poorly understood. On the other hand, UTIs are common in pregnant women and the treatment challenge is alarming.
METHODS AND RESULTS:
In the present study, 54 pregnant women with acute cystitis were included. A total of 108 E. coli isolates, 54 isolates from UTI and 54 isolates from faeces of pregnant women (same host) were collected. In the antimicrobial susceptibility test, the highest rate of antibiotic resistance was to nalidixic acid (77%, 83/108) and the lowest rate was to imipenem (9%, 10/108). Among the isolates, 44% (48/108) were ESBLs producers. A high frequency of PMQR genes was observed in the isolates. The frequency of PMQR genes qnrS, qnrB, aac(6')-Ib-cr, and qnrA was 58% (63/108), 21% (23/108), 9% (10/108), and 4% (4/108), respectively. Meanwhile, PMQR genes were not detected in 24% (20/85) of isolates resistant to nalidixic acid and/or fluoroquinolone, indicating that other mechanisms, i.e. chromosomal mutations, are involved in resistance to quinolones, which were not detected in the present study. In ESBL-producing isolates, the frequency of PMQR genes was higher than that of non-ESBL-producing isolates (81% vs. 53%). Meanwhile, UTI and faeces isolates mainly belonged to phylogenetic group B2 (36/54, 67% and 25/54, 46%, respectively) compared to other phylogenetic groups. In addition, virulence factors and multidrug-resistant (MDR) were mainly associated with phylogenetic group B2. However, predominant clones in faeces were not found in UTIs. Rep-PCR revealed the presence of 85 clones in patients. Among the clones, 40 clones were detected only in faeces (faeces-only), 35 clones only in UTI (UTI-only) and 10 clones in both faeces and UTI (faeces-UTI). We found that out of 10 faeces-UTI clones, 5 clones were present in the host's faeces flora.
CONCLUSION:
This study revealed a high rate of resistance to the quinolone nalidixic acid and a widespread distribution of PMQR genes in MDR E. coli strains producing ESBLs. The strains represented virulence factors and phylogenetic group B2 are closely associated with abundance in UTI and faeces. However, the predominant clones in faeces were not found in UTIs and it is possible that rep-PCR is not sufficiently discriminating clones.
2
项与 萘啶酸 相关的新闻（医药）2024-09-09
MONDAY, Sept. 9, 2024 -- At least 65 people in nine states have been sickened in a salmonella outbreak linked to recalled eggs, U.S. health officials report.
"The nine states include the three states where the eggs were sold -- Illinois, Michigan and Wisconsin -- in addition to California, Colorado, Iowa, Minnesota, Utah and Virginia," the U.S Centers for Disease Control and Prevention said in a
food safety alert
issued on the outbreak. "Most sick people are from Wisconsin [42 cases] or Illinois [11]."
Of 63 cases with information available, 24 have been hospitalized but none have died. Importantly, lab tests have shown the bacteria is resistant to the antibiotics
nalidixic acid
and
ciprofloxacin,
which could make treating the infections tricky, the CDC added. Other
antibiotics
might be needed in those cases.
The potentially contaminated eggs, which were labeled Tony's Fresh Market, have now been recalled due to salmonella contamination. The eggs were supplied by Milo’s Poultry Farms LLC in Bonduel, Wisc., and shipped to stores and restaurants in Illinois, Michigan and Wisconsin, the CDC said.
The recalled eggs should be thrown away or returned to the store. People should wash any items and surfaces that may have touched the recalled eggs with hot, soapy water or a dishwasher, the agency advised.
Salmonella infection can trigger diarrhea, fever and stomach cramps that can begin within hours or days of consuming the bacteria, according to the
U.S. Food and Drug Administration
. Most people will recover without antibiotics, but they should see a health care provider if they have severe symptoms, symptoms that don’t improve after a few days or signs of dehydration.
Children, elderly people and those with weakened immune systems are more likely to become severely ill, the CDC noted.
Whatever your topic of interest,
subscribe to our newsletters
to get the best of Drugs.com in your inbox.
2021-02-09
Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
Market for Penicillin and Combination Drugs Segment to Grow at Highest CAGR during 2020-2027.
The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027.
The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent.
Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment.
R& D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for generic Nitrofurantoin capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used to treat UTI caused by Staphylococcus aureus, enterococci, etc.
Further, in February 2020, a France-based pharmaceutical company announced Exblifep, a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime. i.e., the fourth-generation cephalosporin, which achieved primary endpoints in a clinical trial for complicated UTIs. Moreover, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in boots pharmacies throughout the UK.
Additionally, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr to treat complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In July 2019, the US FDA approved Recarbrio drug to treat cUTI and complicated intra-abdominal infection in adults. In June 2018, Achaogen, Inc. received the US FDA approval for ZEMDRI to treat cUTIs in adults.
In November 2018, Allergan, announced the launch of the FDA accepted supplemental drug AVYCAZ to treat cUTIs and complicated intra-abdominal infections patients between the age group of 3 months to 18 years. Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period.
Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market.
Key Topics Covered:
1. Introduction
2. Urinary Tract Infection Treatment Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Urinary Tract Infection Treatment Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinion
5. Urinary Tract Infection Treatment Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Urinary Tract Infections
5.1.2 Aging Population
5.1.3 Emerging Computing Technologies for Urine Diagnostics
5.2 Market Restraints
5.2.1 Associated Effects of Medication
5.3 Market Opportunities
5.3.1 R&D in UTI Treatment
5.4 Future Trends
5.4.1 Nutritional Supplement in UTI
6. Urinary Tract Infection Treatment Market - Global Analysis
6.1 Global Urinary Tract Infection Treatment Market Revenue Forecast and Analysis
6.2 Global Urinary Tract Infection Treatment Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Urinary Tract Infection Treatment Market Analysis - By Drug Class
7.1 Overview
7.2 Urinary Tract Infection Treatment Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Penicillin and Combinations
7.3.1 Overview
7.3.2 Penicillin and Combinations: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million)
7.3.3 Amoxicillin
7.3.4 Amoxicillin and Clavulanate Potassium
7.4 Quinolones
7.4.1 Overview
7.4.2 Quinolones: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million)
7.4.3 Ciprofloxaxin
7.4.4 Levofloxaxin
7.4.5 Nalidixic Acid
7.4.6 Norfloxacin
7.4.7 Others
7.5 Cephalosporin
7.6 Aminoglycoside Antibiotics
7.7 Sulphonamides
7.8 Nutritional Supplements
7.8.1 Overview
7.8.2 Nutritional Supplements: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million)
7.8.3 Cranberry Supplements
7.8.4 D-Mannose
7.8.5 Probiotics
7.8.6 Vitamin-C
8. Urinary Tract Infection Treatment Market Analysis - By Indication
8.1 Overview
8.2 Urinary Tract Infection Treatment Market Revenue Share, by Indication (2019 and 2027)
8.3 Complicated Urinary Tract Infections
8.4 Uncomplicated Urinary Tract Infections
9. Urinary Tract Infection Treatment Market Analysis - By Distribution Channel
9.1 Overview
9.2 Urinary Tract Infection Treatment Market Revenue Share, by Distribution Channel (2019 and 2027)
9.3 Hospital Pharmacies
9.4 Retail Pharmacies & Drug Stores
9.5 Gynaecology and Urology Clinics
9.6 Online Drug Stores
10. Urinary Tract Infection Treatment Market - Geographic Analysis
11. Impact of COVID-19 Pandemic on Global Urinary Tract Infection Treatment Market
12. Urinary Tract Infection Treatment Market-Industry Landscape
Companies Mentioned
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Mylan N.V.
ALLERGAN
Pfizer Inc.
Cipla Ltd
F. Hoffmann-La Roche Ltd
Shionogi Inc.
Amway
DuPont Nutrition & Biosciences
For more information about this report visit
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
合作
100 项与 萘啶酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泌尿道感染 | 美国 | 1964-03-06 |
登录后查看更多信息
临床结果
临床结果
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用